Vigil Neuroscience Inc (VIGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vigil Neuroscience Inc (VIGL) has a cash flow conversion efficiency ratio of -0.496x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.48 Million) by net assets ($41.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vigil Neuroscience Inc (VIGL) balance sheet quality index to measure how much of total assets are equity-financed.
Vigil Neuroscience Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Vigil Neuroscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Vigil Neuroscience Inc (VIGL) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Vigil Neuroscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vigil Neuroscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baotek Industrial Materials Ltd
TWO:5340
|
0.070x |
|
Five Point Holdings LLC
NYSE:FPH
|
-0.019x |
|
Zhejiang Aokang Shoes Co Ltd
SHG:603001
|
0.002x |
|
Yantai Zhenghai Bio-Tech Co Ltd
SHE:300653
|
0.035x |
|
Zhongxing Shenyang Commercial Building Group Co Ltd
SHE:000715
|
0.029x |
|
Xinjiang Torch Gas Co Ltd
SHG:603080
|
0.075x |
|
BTS Group AB (publ)
ST:BTS-B
|
-0.001x |
|
Meteoric Resources NL
F:RNF
|
-0.820x |
Annual Cash Flow Conversion Efficiency for Vigil Neuroscience Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Vigil Neuroscience Inc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see VIGL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.64 Million | $-51.22 Million | -0.715x | -18.14% |
| 2023-12-31 | $116.25 Million | $-70.36 Million | -0.605x | -75.66% |
| 2022-12-31 | $189.08 Million | $-65.15 Million | -0.345x | -160.81% |
| 2021-12-31 | $-69.44 Million | $-39.35 Million | 0.567x | +209.37% |
| 2020-12-31 | $-28.28 Million | $-5.18 Million | 0.183x | -- |
About Vigil Neuroscience Inc
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells… Read more